TERNS PHARMACEUTICALS INC. - COMMON STOCK

Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

05 фев 2025 15:05:00 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

03 фев 2025 15:05:00 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

08 янв 2025 15:05:00 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

02 янв 2025 15:05:00 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia

03 дек 2024 06:00:00 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

02 дек 2024 15:05:00 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

18 ноя 2024 15:05:00 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates

12 ноя 2024 15:05:00 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences

06 ноя 2024 15:05:00 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

07 окт 2024 15:05:00 Источник Nasdaq GlobeNewswire

Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

12 сен 2024 18:00:00 Источник Nasdaq GlobeNewswire

Terns Announces Pricing of Upsized $150.15 Million Public Offering

10 сен 2024 21:50:00 Источник Nasdaq GlobeNewswire

Terns Announces Proposed Public Offering

09 сен 2024 15:01:00 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

09 сен 2024 06:05:00 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates

05 авг 2024 15:05:00 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

01 авг 2024 15:05:00 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition

29 июл 2024 15:05:00 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation

21 июн 2024 17:30:00 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

03 июн 2024 15:10:00 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

30 май 2024 07:05:00 Источник Nasdaq GlobeNewswire